These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 17251298)

  • 1. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.
    Hatada M; Yoshimura K; Harada S; Kawanami Y; Shibata J; Matsushita S
    J Gen Virol; 2010 May; 91(Pt 5):1335-45. PubMed ID: 20032207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope.
    Takizawa M; Miyauchi K; Urano E; Kusagawa S; Kitamura K; Naganawa S; Murakami T; Honda M; Yamamoto N; Komano J
    AIDS; 2011 Nov; 25(18):2209-16. PubMed ID: 21866041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
    Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K
    Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
    Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J
    Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1.
    Inouye P; Cherry E; Hsu M; Zolla-Pazner S; Wainberg MA
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):735-40. PubMed ID: 9643373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
    Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
    J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypic and phenotypic characterization of a neutralization-resistant breakthrough population of HIV-1.
    Sirko DA; Ehrlich GD
    Virology; 1996 Apr; 218(1):238-42. PubMed ID: 8615028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
    Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes.
    Jagodzinski PP; Wustner J; Kmieciak D; Wasik TJ; Fertala A; Sieron AL; Takahashi M; Tsuji T; Mimura T; Fung MS; Gorny MK; Kloczewiak M; Kaneko Y; Kozbor D
    Virology; 1996 Dec; 226(2):217-27. PubMed ID: 8955041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region.
    Masuda T; Matsushita S; Kuroda MJ; Kannagi M; Takatsuki K; Harada S
    J Immunol; 1990 Nov; 145(10):3240-6. PubMed ID: 1700002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
    Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
    Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.